Abstract
The generics market remains a major growth area in the global healthcare
market. That growth has been partly driven by cost-containment in several
national healthcare sectors, with governments seeking to promote the use of
generic products over higher-priced originator products. The global generic
pharmaceuticals market was worth over $100bn in 2007, with market growth
noticeably higher that that of the overall pharmaceutical market. Our new
report - World Generics Market, 2008-2013 - will help you to understand the
key developments in this sector and their significance, from the present
looking forward. The report provides valuable commercial information on this
exciting sector, one that no pharmaceutical company or related organisation
can afford to ignore.
Over the period 2008 to 2013, visiongain foresees the generic market to
sustain its strong current growth, with exciting new developments to be driven
by the wave of blockbuster drugs approaching patent expiry. This report -
World Generics Market, 2008-2013 - provides details of these drugs and
potential generics revenues. The study also identifies the therapeutic areas
that will face the highest levels of competition from generic substitutes from
2008 to 2013. Our report examines the global generics market and industry
critically, with in-depth analysis, especially market forecasting and
qualitative analysis of market drivers and restraints. The result is a
comprehensive market-based report with detailed analysis and informed opinion.
Why you should buy this report
In particular, World Generics Market, 2008-2013 concentrates on the following
essential aspects of the generics market and industry:
- Discussion of key issues affecting the global generics market and the
wider pharmaceutical market/industry
- Why governments and healthcare organisations - including private insurers
- are increasingly opting for generic medicines; we provide country-specific
information there
- Discussion of drivers and opportunities in the generics sector
- Discussion of restraints and threats in the generics sector
- Sales forecasts from 2008-2013 for the global generics market and leading
national generics markets - US, Japan, Germany, France, UK, Spain, Italy
- Discussion of developing generics markets, especially China, India and
Russia, with major industrial developments covered.
Despite the potentially great opportunities to be harnessed by generics
companies in both developed and developing countries, there remain marked
obstacles to be overcome. While many generics companies are becoming larger
and more innovative, originator drugs companies - especially top-10 pharma
companies - are generally prepared for the threat from generics, having
developed strategies to minimise the effects of sales erosion. Still, there
are large potential losses in sales occurring currently - and likely to
continue in the years ahead - as one blockbuster drug after another faces
direct and indirect generic competition.
Certainly, the commercial opportunities for dynamic generics companies are
great. Similarly, the cost-saving opportunities for both public and private
healthcare providers worldwide are significant. By purchasing this report, you
will be better able to appreciate those major developments in the global
pharmaceutical market, with many stakeholders affected.
| 
View Cart
